Kathy Hopinkah Hannan - Jun 16, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Director
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Jun 16, 2023
Transactions value $
$0
Form type
4
Date filed
6/21/2023, 05:05 PM
Previous filing
May 22, 2023
Next filing
Oct 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Award $0 +105K $0.00 105K Jun 16, 2023 Class A Common Stock 105K $0.00 Direct F1, F2
transaction DNA Stock Option Award $0 +140K $0.00 140K Jun 16, 2023 Class A Common Stock 140K $1.90 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 16, 2024 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date. RSUs granted on August 2, 2022 that were initially reported as Class A Common Stock in Table I of a Form 4 dated August 4, 2022 vested in full in shares on June 15, 2023.
F3 In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.